menu
    • menu
    [{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TJ-68","moa":"Dopamine transporter","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Tsumura & Co \/ Tsumura & Co","highestDevelopmentStatusID":"7","companyTruncated":"Tsumura & Co \/ Tsumura & Co"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Rikkunshito","moa":"Ghrelin receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Tsumura & Co","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Tsumura & Co"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Cato Research","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Daikenchuto","moa":"Gut microbiome","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Tsumura & Co \/ Cato Research","highestDevelopmentStatusID":"7","companyTruncated":"Tsumura & Co \/ Cato Research"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Syneos Health"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Icon Plc","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Icon Plc"},{"orgOrder":0,"company":"Tsumura & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"Tsumura & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tsumura & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tsumura & Co \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Tsumura & Co

    Menu

    Tsumura & Co

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TJ-68

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : Hiroshi Mitsumoto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

                            Details : TJ-68 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 10, 2021

                            Lead Product(s) : TJ-68

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Hiroshi Mitsumoto

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TU-100

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel...

                            Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 08, 2021

                            Lead Product(s) : TU-100

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rikkunshito

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Recipient : Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Rikkunshito on Gastric Accommodation and Nutrient Volume Tolerance in Functional Dyspepsia

                            Details : Rikkunshito is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyspepsia.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 27, 2019

                            Lead Product(s) : Rikkunshito

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Recipient : Universitaire Ziekenhuizen KU Leuven

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy

                            Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 05, 2014

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TU-100

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irri...

                            Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 28, 2014

                            Lead Product(s) : TU-100

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)

                            Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Irritable Bowel Syndrome.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            July 02, 2013

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TU-100

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

                            Details : TU-100 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Crohn Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 07, 2011

                            Lead Product(s) : TU-100

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of TU-100 in Patients With Functional Constipation

                            Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 05, 2011

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed

                            Tsumura & Co

                            Japan arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of TU-100 on Rectal Compliance, Rectal Sensation and Small Bowel and Colonic Transit in Females With Co...

                            Details : Daikenchuto is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Constipation.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 08, 2010

                            Lead Product(s) : Daikenchuto

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Cato Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth